Text Size
18 studies found for:    benzamide

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation
Condition: Clozapine-induced Hypersalivation
Intervention: Drug: Amisulpride, Moclobemide
2 Completed An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)
Condition: Advanced Solid Tumors
Intervention: Drug: iniparib
3 Active, not recruiting Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
Condition: Advance Solid Tumors
Interventions: Drug: Iniparib (SAR240550 - BSI-201);   Drug: Gemcitabine;   Drug: Carboplatin
4 Recruiting Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine;   Drug: Fosaprepitant Placebo;   Drug: Dexamethasone;   Drug: Ondansetron;   Drug: Dexamethasone Placebo;   Drug: Ondansetron Placebo;   Drug: Rescue Therapy
5 Recruiting A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC)
Conditions: Nausea;   Vomiting
Interventions: Drug: Aprepitant;   Drug: Aprepitant Placebo;   Drug: Ondansetron;   Drug: Dexamethasone;   Drug: Ondansetron Placebo;   Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
6 Unknown † Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Condition: Chromaffin-tissue Derived Tumors
Intervention: Other: Scintigraphy in 123I-IBZM
7 Completed A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Conditions: Myelodysplastic Syndrome;   Acute Myelogenous Leukemia
Intervention: Drug: MGCD0103
8 Completed A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MGCD0103
9 Completed Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Tumors;   Non Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
10 Completed A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Condition: Tumors
Interventions: Drug: MGCD0103;   Drug: Gemcitabine
11 Completed A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Intervention: Drug: MGCD0103
12 Terminated Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Conditions: Breast Cancer;   Lung Cancer;   Pulmonary Cancer;   Non-Small-Cell Lung Carcinoma;   Prostate Cancer;   Prostatic Cancer;   Gastric Cancer;   Stomach Cancer
Intervention: Drug: MGCD0103 & Docetaxel
13 Terminated Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
14 Terminated MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Intervention: Drug: MGCD0103 and Azacitidine
15 Completed Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Condition: Lymphoma
Intervention: Drug: MGCD0103
16 Completed A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MGCD0103
17 Terminated MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Conditions: Myelogenous Leukemia, Acute;   Myelodysplastic Syndromes
Intervention: Drug: MGCD0103
18 Terminated Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Interventions: Drug: Azacitidine;   Drug: MGCD0103
To Top

† Indicates status has not been verified in more than two years